Prasad Kedar N
Engage Global, 245 El-Faisan Drive, San Rafael, CA 94903, United States.
Curr Aging Sci. 2017;10(3):177-184. doi: 10.2174/1874609810666170102144233.
Parkinson's disease (PD) is a slow progressive neurodegenerative disease associated with abnormal function of extrapyramidal system. Although several biochemical and genetic defects are identified, increased oxidative stress and chronic inflammation are one of the earliest events that initiate and promote PD. Oxidative stress also participates in impaired nonmotor symptoms. The levels of microRNAs that are evolutionarily conserved single-stranded noncoding RNAs of approximately 22 nucleotide in length may have a role in PD.
Published studies on changes in the levels of microRNAs in PD were critically reviewed, and the role of Reactive Oxygen Species (ROS), pro-inflammatory cytokines, and antioxidants in regulating the levels of microRNAs was evaluated.
MicroRNAs levels were altered in PD. Downregulated microRNAs cause neurodegeneration by decreasing the levels of Nrf2 (nuclear transcriptional factor-2), mTOR (mammalian target of rapamycin), and DJ-1 and Parkin genes; and by increasing the levels of alpha-synuclein, RelA, Bim and Calpain-1, and A2AR (adenosine A2A receptor). Upregulated microRNAs cause degeneration of nerve cells by decreasing the levels of IGF-1 (Insulin Growth Factor-1), GRP78 (glucose regulated protein 78), DJ-1, and Hsc-70 (Heat- Shock Protein-70) that enhanced alpha-synuclein levels. ROS and pro-inflammatory cytokines cause neurodegeneration by altering the levels of microRNAs. Antioxidants that protect neurons by reducing oxidative stress and chronic inflammation altered the levels of microRNAs.
Increased oxidative stress and chronic inflammation may cause neurodegeneration in PD by altering the levels of microRNAs and their target proteins. Antioxidants may provide neuroprotection by changing the levels of microRNAs and their target proteins.
帕金森病(PD)是一种与锥体外系功能异常相关的缓慢进展性神经退行性疾病。尽管已发现多种生化和基因缺陷,但氧化应激增加和慢性炎症是引发和促进PD的最早事件之一。氧化应激还参与非运动症状的损害。长度约为22个核苷酸的进化保守单链非编码RNA——微小RNA的水平可能在PD中起作用。
对已发表的关于PD中微小RNA水平变化的研究进行严格综述,并评估活性氧(ROS)、促炎细胞因子和抗氧化剂在调节微小RNA水平中的作用。
PD中微小RNA水平发生改变。微小RNA下调通过降低核转录因子2(Nrf2)、雷帕霉素哺乳动物靶蛋白(mTOR)、DJ-1和帕金基因的水平;以及通过增加α-突触核蛋白、RelA、Bim和钙蛋白酶-1以及腺苷A2A受体(A2AR)的水平导致神经退行性变。微小RNA上调通过降低胰岛素样生长因子1(IGF-1)、葡萄糖调节蛋白78(GRP78)、DJ-1和热休克蛋白70(Hsc-70)的水平导致神经细胞变性,而这些蛋白水平的降低会提高α-突触核蛋白水平。ROS和促炎细胞因子通过改变微小RNA水平导致神经退行性变。通过减少氧化应激和慢性炎症来保护神经元的抗氧化剂会改变微小RNA水平。
氧化应激增加和慢性炎症可能通过改变微小RNA及其靶蛋白的水平导致PD中的神经退行性变。抗氧化剂可能通过改变微小RNA及其靶蛋白的水平提供神经保护作用。